Call Us + 33 1 84 88 31 00

Article R5121-13 of the French Public Health Code

Subject to the provisions of articles L. 1123-6 to L. 1123-8 and L. 1123-13 and those adopted for their application, the investigators and persons called upon to collaborate in the trials are bound by professional secrecy concerning in particular the nature of the products studied, the trials, the persons taking part in them and the results obtained. Without the agreement of the sponsor, they may only give information relating to…

Read More »

Article R5121-14 of the French Public Health Code

The sponsor shall provide the investigators of chemical, pharmaceutical, biological, pharmacological or toxicological tests with: 1° The title and objective of the test requested ; 2° Identification of the medicinal product to be tested: a) Its special or scientific name or its code name ; b) Its pharmaceutical form ; c) Its qualitative and quantitative composition, using the international non-proprietary names where they exist or, failing this, the names of…

Read More »

Article R5121-15 of the French Public Health Code

The sponsor provides clinical trial investigators with : 1° The title and objective of the trial requested; 2° The pharmaceutical form, batch number(s) and expiry date of the investigational medicinal product; 3° For the investigational medicinal product or the medicinal product used as a reference, its special or scientific name or its code name, its qualitative and quantitative composition in terms of active substances and excipient constituents, knowledge of which…

Read More »

Article R5121-16 of the French Public Health Code

Investigational medicinal products are prepared in accordance with the good practices mentioned in article L. 5121-5. The information appearing on the labelling must be written at least in French. The labelling must guarantee the protection of the person undergoing the research and traceability, enable the product and the trial to be identified and facilitate the appropriate use of the investigational medicinal product. The content of the labelling of these medicinal…

Read More »

Article R5121-20 of the French Public Health Code

Each chemical, pharmaceutical, biological and non-clinical trial gives rise to a report drawn up by the investigator who carried out the trial. This report, dated and signed, states in particular: 1° The identity of the investigator(s), their qualifications, experience and duties ; 2° The dates and places where the trial was conducted; 3° The information mentioned in 2° and 3° of article R. 5121-14.

Read More »

Article R5121-21 of the French Public Health Code

The application for marketing authorisation is sent to the Director General of the Agence nationale de sécurité du médicament et des produits de santé. It must state : 1° The name and address of the future marketing authorisation holder and, where applicable, those of the company exploiting the proprietary medicinal product, as well as those of the manufacturer where neither the future marketing authorisation holder nor the company exploiting the…

Read More »

Article R5121-21-1 of the French Public Health Code

Where an application for marketing authorisation in France is made for a medicinal product which has already been authorised or is the subject of an application for marketing authorisation currently being examined in another Member State of the European Community or a State which is a party to the Agreement on the European Economic Area, without complying with the provisions of Subsection 3a of this Section, the Director General of…

Read More »

Article R5121-21-2 of the French Public Health Code

The applicant is responsible for the accuracy and truthfulness of the documents and data supplied to the Agency when the application for marketing authorisation is submitted and during its examination. The applicant must inform the Agency without delay of any new information available or of which he is aware, in particular the results of biomedical studies or research carried out in or outside the European Community or the European Economic…

Read More »

Article R5121-22 of the French Public Health Code

Where the application for marketing authorisation concerns a generator, it shall also include: 1° A general description of the system and a detailed description of the components of the system likely to affect the composition or quality of the preparation of the daughter nuclide; 2° The qualitative and quantitative characteristics of the eluate or sublimate.

Read More »

Contact a French lawyer now

Contact a French Business Lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.